reports hero background
Updated: Nov 20, 2026
DWTX Logo

Dogwood Therapeutics

NASDAQ:DWTX·Stock Analysis Report
Day Range
$0.99 - $1.10
Market Cap
40.52M
P/E Ratio
0.1033
Avg Value
$3.97
Year Range
$0.90 - $7.04
$1.04-$0.03 (-2.36%)
1
General Information
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy.

The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.

2
Dogwood Therapeutics (DWTX) Stock Graph
3
How We Grade Dogwood Therapeutics (DWTX)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade Dogwood Therapeutics (DWTX) across the board compared to its closest peers.

4
Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

5
Peer Ratings

See how Dogwood Therapeutics compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
NMADNomad Power Solutions
N/A
N/A
N/A
N/A
CNTBConnect Biopharma Hldgs
N/A
N/A
N/A
N/A
ELTXElicio Therapeutics
N/A
N/A
N/A
N/A
BMEABiomea Fusion
N/A
N/A
N/A
N/A
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
6
Financial Health
What is the current state of the company's financial situation?

We measure the health of a company based on how profitable they are and their ability to cover both their short-term and long-term debts. The key indicators that we use are the Operating Margin, Quick Ratio, and Debt-to-Equity ratio relative to the companies peers

Operational Margin -49.1730

The operating margin measures how much profit a company makes after it spends money on wages, materials or other administrative expenses but before interest and taxes. It is a good representation of how efficiently a company is able to generate profit from its core operations.

Quick Ratio 2.2760

The quick ratio measures how much of a company's debt, that is due in less than 1 year, can be covered using its cash equivalents, marketable securities, and money that is currently owed to them (accounts receivables).

A company with a quick ratio of less than 1.00 does not, in many cases, have the capital on hand to meet its short-term obligations if they were all due at once, while a quick ratio greater than one indicates the company has the financial resources to remain solvent in the short term.

Debt-to-Equity 0.1789

Debt-to-equity is calculated by dividing a company's total liabilities by its shareholders equity. It is a measure of the degree to which a company is financing its operations through debt versus wholly owned funds. Generally speaking, a D/E ratio below 1.0 would be seen as relatively safe, whereas ratios of 2.0 or higher would be considered risky.

The chart above shows Dogwood Therapeutics (DWTX) operating margin, quick ratio, and debt-to-equity ratio compared to its peers. The black markers represent the peer averages for each ratio and the blue bars represent Dogwood Therapeutics (DWTX) ratio values.
7
Past Performance
How has Dogwood Therapeutics (DWTX) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

Dogwood Therapeutics (DWTX) sharpe ratio over the past 5 years is -0.0492 which is considered to be above average compared to the peer average of -0.2280


BenzingaBenzinga Korea 한국